dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
  • Home
  • CompanyCassiopea SpA

December 23, 2020: Cassiopea SpA

Cassiopea Announces Management Change

Pierpaolo Guzzo to replace Chris Tanner as Chief Financial Officer

Cassiopea SpA, today announced that Chris Tanner is retiring as Chief Financial Officer as of December 31, 2020. Chris Tanner served as Cassiopea’s Chief Financial Officer since its formation and helped bring the Company public in 2015. At the meeting of December 22, 2020, the board approved the nomination of Pierpaolo Guzzo as Chief Financial Officer of Cassiopea starting January 1, 2021. Pierpaolo Guzzo is a Certified Public Accountant, with an extensive track record in accounting, private equity and merchant banking; he will retain his role as board member of Cassiopea.

Please read the whole article here

News 2020

October 8, 2020: Cassiopea SpA

Cassiopea Announces Completion of Enrollment in a Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Females

Cassiopea SpA, today announced that it has completed the enrollment of its phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females.

Please read the whole article here

News 2020

August 27, 2020: Cassiopea SpA

Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor

The approval of WINLEVI brings the first truly new mechanism of action in acne treatment in nearly 40 years

Cassiopea SpA, today announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older. Notwithstanding acne being the most prevalent skin condition in the U.S. affecting up to 50 million Americans annually1, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago.

Please read the whole article here

News 2020

July 29, 2020: Cassiopea SpA

Cassiopea Announces Results for First Half of 2020

Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced its half-year 2020 results for the period ended 30 June 2020.

Please read the whole article here

News 2020

June 23, 2020: Cassiopea SpA

Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne

Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced the publication of positive safety data from a long-term extension study evaluating Clascoterone cream 1% for acne in the online issue of Journal of the American Academy of Dermatology (JAAD).

Please read the whole article here

News 2020

May 29, 2020: Cassiopea SpA

Cassiopea announces results of extraordinary shareholders meeting

Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced the results of the extraordinary shareholders meeting held on 28 May 2020 in Lainate.

Please read the whole article here

News 2020

May 29, 2020: Cassiopea SpA

Cassiopea announces EUR 23.25 million capital increase by way of rights offering through the issuance of 750,000 shares at an offer price of EUR 31.00 per share

Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announces a capital increase by way of a rights offering to existing shareholders.

Please read the whole article here

News 2020

May 28, 2020: Cassiopea SpA

Cassiopea Announces Results for First Quarter 2020

Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today its interim first quarter results for the period ended 31 March 2020.

Please read the whole article here

News 2020

April 30, 2020: Cassiopea SpA

Cassiopea announces results of ordinary shareholders meeting

Cassiopea SpA, a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the results of the shareholders meeting held on April 29, 2020 in Lainate.

Please read the whole article here

News 2020

April 21, 2020: Cassiopea SpA

Lists of candidates for the board of directors at the AGM 2020

Cassiopea SpA, a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the lists of candidates proposed for the board of directors at the Annual General Meeting of 29 April 2020, in Lainate, Milan (Italy).

Please read the whole article here
News 2020
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz